drugset / Trial / NCT02288845

Receptor Occupancy of ITI-007 Using Positron Emission Tomography (PET) in Patients With Stable Schizophrenia

NCT02288845

Phase 2 Completed 14 enrolled Intra-Cellular Therapies, Inc.
NaSingle-groupOpen-labelBasic science

Summary

The purpose of this study is to determine the relationship between ITI-007 dose, plasma levels and brain receptor occupancy in patients with stable schizophrenia.

Timeline

Start
2014-10
Primary completion
2015-07
Completion
2015-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Lumateperone Small molecule Oral

Indications